This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Juno Therapeutics Gmbh. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Samriti Bedi: Innovator in Antibody Research
Introduction
Samriti Bedi is a prominent inventor based in Newcastle, WA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies and chimeric antigen receptors.
Latest Patents
Samriti Bedi holds a patent for "Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)." This patent includes receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, specifically human antibodies that target ROR1, including antibody fragments. The patent also covers recombinant receptors, such as chimeric antigen receptors (CARs) that incorporate these antibodies or fragments, along with polynucleotides encoding the antibodies, antigen-binding fragments, or receptors specific for ROR1. Furthermore, it discusses genetically engineered cells containing these ROR1-binding proteins and receptors, along with related methods and applications in adoptive cell therapy.
Career Highlights
Samriti Bedi is currently associated with Juno Therapeutics GmbH, where he continues to advance his research in antibody technology. His work has the potential to impact therapeutic strategies for various diseases.
Collaborations
Some of his notable coworkers include Andreia Costa and Rupesh Amin, who contribute to the innovative environment at Juno Therapeutics GmbH.
Conclusion
Samriti Bedi's work in antibody research and his patent on ROR1-targeting molecules exemplify his commitment to advancing medical science. His contributions are paving the way for new therapeutic approaches in the field of biotechnology.